# Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

> **NCT03943537** · PHASE2 · COMPLETED · sponsor: **Mclean Hospital** · enrollment: 87 (actual)

## Conditions studied

- Psychosis
- Schizophrenia
- Schizo Affective Disorder
- Bipolar I Disorder

## Interventions

- **DRUG:** Intranasal Insulin

## Key facts

- **NCT ID:** NCT03943537
- **Lead sponsor:** Mclean Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-01
- **Primary completion:** 2024-02-23
- **Final completion:** 2024-02-23
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03943537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03943537, "Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03943537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*